Cell and Gene Therapy Biomanufacturing Market - A Global and Regional Analysis: Focus on Product Type, Application, Usage, End User, and Region - Analysis and Forecast, 2022-2031

Table of Contents

1 Markets

• 1.1 Market Outlook
  • 1.1.1 Product Definition
  • 1.1.2 Inclusion and Exclusion Criteria
  • 1.1.3 Key Findings
  • 1.1.4 Assumptions and Limitations
  • 1.1.5 Market Growth Scenarios
    • 1.1.5.1.1 Realistic Growth Scenario
    • 1.1.5.1.2 Optimistic Growth Scenario
    • 1.1.5.1.3 Pessimistic Growth Scenario
• 1.2 Industry Outlook
  • 1.2.1 Market Overview and Ecosystem
  • 1.2.2 Key Trends
    • 1.2.2.1 Biomanufacturing 4.0
    • 1.2.2.2 Growing Single-Use Technology Market Penetration
    • 1.2.2.3 Shift from Open Processing to Closed Processing for Cell and Gene Therapy Biomanufacturing
    • 1.2.2.4 Leveraging Various Key Strategies to Diversify the Product Portfolio
  • 1.2.3 Opportunity Assessment
  • 1.2.4 Regulatory Framework
  • 1.2.5 Product Benchmarking
    • 1.2.5.1 Product Benchmarking (by Product Type)
    • 1.2.5.2 Comparative Analysis (by Equipment)
  • 1.2.6 Patent Analysis
    • 1.2.6.1 Patent Analysis (by Year)
    • 1.2.6.2 Patent Analysis (by Country)
    • 1.2.6.3 Awaited Technologies
  • 1.2.7 Business Model Analysis
  • 1.2.8 Pipeline Products
  • 1.2.9 Technology Adoption Matrix
  • 1.2.10 Funding Scenario
  • 1.2.11 Key Success Factors
• 1.3 Business Dynamics
  • 1.3.1 Business Drivers
    • 1.3.1.1 Increasing Number of Approved Therapies and Growing Infrastructure Requirements Creating an Upsurge Demand for Cell and Gene Therapy Biomanufacturing Products
    • 1.3.1.2 Expansion in Target Indications for Cell and Gene Therapies Creating a Demand for Large-Scale Biomanufacturing
    • 1.3.1.3 Entry of New Market Participants in Cell and Gene Therapies Driving the Demand for Biomanufacturing Facilities and Equipment
    • 1.3.1.4 Increasing Investments and Fundings in Cell and Gene Therapy Fuelling the Growth of Cell and Gene Therapy Biomanufacturing
    • 1.3.1.5 Impact Analysis
  • 1.3.2 Business Restraints
    • 1.3.2.1 High Set-Up Cost of Biomanufacturing Facilities
    • 1.3.2.2 Impact Analysis
  • 1.3.3 Business Opportunities
    • 1.3.3.1 Integration of Automation into the Cell and Gene Therapy Biomanufacturing Workflow
    • 1.3.3.2 Robust Clinical Pipeline Creating a Demand for Biomanufacturing Infrastructure
• 1.4 Impact of COVID-19 on the Cell and Gene Therapy Biomanufacturing Market
  • 1.4.1 Recommendations to Manufacturers
• 1.5 Impact of Russo-Ukrainian War on Cell and Gene Therapy Biomanufacturing Market

2 Global Cell and Gene Therapy Biomanufacturing Market (by Product Type)

• 2.1 Overview
• 2.2 Opportunity Assessment
• 2.3 Consumables
  • 2.3.1 Culture Supplements
    • 2.3.1.1 Media
    • 2.3.1.2 Serum
    • 2.3.1.3 Macronutrients
  • 2.3.2 Single-Use Liquids
  • 2.3.3 Cell Culture Reagents
  • 2.3.4 Cell Quantification Kits
• 2.4 Equipment
  • 2.4.1 Bioreactors/Fermenters
    • 2.4.1.1 Continuous Bioreactors
    • 2.4.1.2 Single-Use Bioreactors
  • 2.4.2 Mixing Systems
  • 2.4.3 Cell Counters
  • 2.4.4 Cell Sorters
  • 2.4.5 Centrifuges
  • 2.4.6 Incubators
  • 2.4.7 Biosafety Cabinets
  • 2.4.8 Freezers
  • 2.4.9 PCR Systems
  • 2.4.10 Transfection Systems
  • 2.4.11 Storage Tanks
  • 2.4.12 Others
• 2.5 Software Solutions

3 Global Cell and Gene Therapy Biomanufacturing Market (by Application)

• 3.1 Overview
• 3.2 Opportunity Assessment
• 3.3 Upstream Processing
  • 3.3.1 Formulation and Hydration
  • 3.3.2 Cell Culture Processing
• 3.4 Harvesting
• 3.5 Downstream Processing
  • 3.5.1 Separation and Filtration
  • 3.5.2 Fill and Finish Operations

4 Global Cell and Gene Therapy Biomanufacturing Market (by Usage)

• 4.1 Overview
• 4.2 Opportunity Assessment
• 4.3 Commercial Stage Manufacturing
• 4.4 Research Stage Manufacturing

5 Global Cell and Gene Therapy Biomanufacturing Market (by End User)

• 5.1 Overview
• 5.2 Opportunity Assessment
• 5.3 Life Sciences Companies
  • 5.3.1 Equipment
  • 5.3.2 Consumables
  • 5.3.3 Software Solutions
• 5.4 Contract Research Organizations (CROs)
  • 5.4.1 Equipment
  • 5.4.2 Consumables
  • 5.4.3 Software Solutions
• 5.5 Contract Manufacturing Organizations (CMOs)
  • 5.5.1 Equipment
  • 5.5.2 Consumables
  • 5.5.3 Software Solutions
• 5.6 Cell Banks
  • 5.6.1 Equipment
  • 5.6.2 Consumables
  • 5.6.3 Software Solutions

6 Global Cell and Gene Therapy Biomanufacturing Market (by Region)

• 6.1 North America
  • 6.1.1 Key Findings and Opportunity Assessment
  • 6.1.2 Market Dynamics
    • 6.1.2.1 Impact Analysis
  • 6.1.3 Sizing and Forecast Analysis
    • 6.1.3.1 North America Cell and Gene Therapy Biomanufacturing Market (by Product Type)
    • 6.1.3.2 North America Cell and Gene Therapy Biomanufacturing Market (by End User)
    • 6.1.3.3 North America Cell and Gene Therapy Biomanufacturing Market (by Country)
      • 6.1.3.3.1 U.S.
        • 6.1.3.3.1.1 U.S. Cell and Gene Therapy Biomanufacturing Market (by Product Type)
        • 6.1.3.3.1.2 U.S. Cell and Gene Therapy Biomanufacturing Market (by End User)
      • 6.1.3.3.2 Canada
        • 6.1.3.3.2.1 Canada Cell and Gene Therapy Biomanufacturing Market (by Product Type)
        • 6.1.3.3.2.2 Canada Cell and Gene Therapy Biomanufacturing Market (by End User)
• 6.2 Europe
  • 6.2.1 Key Findings and Opportunity Assessment
  • 6.2.2 Market Dynamics
    • 6.2.2.1 Impact Analysis
  • 6.2.3 Sizing and Forecast Analysis
    • 6.2.3.1 Europe Cell and Gene Therapy Biomanufacturing Market (by Product Type)
    • 6.2.3.2 Europe Cell and Gene Therapy Biomanufacturing Market (by End User)
    • 6.2.3.3 Europe Cell and Gene Therapy Biomanufacturing Market (by Country)
      • 6.2.3.3.1 Germany
        • 6.2.3.3.1.1 Germany Cell and Gene Therapy Biomanufacturing Market (by Product Type)
        • 6.2.3.3.1.2 Germany Cell and Gene Therapy Biomanufacturing Market (by End User)
      • 6.2.3.3.2 Italy
        • 6.2.3.3.2.1 Italy Cell and Gene Therapy Biomanufacturing Market (by Product Type)
        • 6.2.3.3.2.2 Italy Cell and Gene Therapy Biomanufacturing Market (by End User)
      • 6.2.3.3.3 U.K.
        • 6.2.3.3.3.1 U.K. Cell and Gene Therapy Biomanufacturing Market (by Product Type)
        • 6.2.3.3.3.2 U.K. Cell and Gene Therapy Biomanufacturing Market (by End User)
      • 6.2.3.3.4 Spain
        • 6.2.3.3.4.1 Spain Cell and Gene Therapy Biomanufacturing Market (by Product Type)
        • 6.2.3.3.4.2 Spain Cell and Gene Therapy Biomanufacturing Market (by End User)
      • 6.2.3.3.5 France
        • 6.2.3.3.5.1 France Cell and Gene Therapy Biomanufacturing Market (by Product Type)
        • 6.2.3.3.5.2 France Cell and Gene Therapy Biomanufacturing Market (by End User)
      • 6.2.3.3.6 Rest-of-Europe
        • 6.2.3.3.6.1 Rest-of-Europe Cell and Gene Therapy Biomanufacturing Market (by Product Type)
        • 6.2.3.3.6.2 Rest-of-Europe Cell and Gene Therapy Biomanufacturing Market (by End User)
• 6.3 Asia-Pacific
  • 6.3.1 Key Findings and Opportunity Assessment
  • 6.3.2 Market Dynamics
    • 6.3.2.1 Impact Analysis
  • 6.3.3 Sizing and Forecast Analysis
    • 6.3.3.1 Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Product Type)
    • 6.3.3.2 Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by End User)
    • 6.3.3.3 Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Country)
      • 6.3.3.3.1 China
        • 6.3.3.3.1.1 China Cell and Gene Therapy Biomanufacturing Market (by Product Type)
        • 6.3.3.3.1.2 China Cell and Gene Therapy Biomanufacturing Market (by End User)
      • 6.3.3.3.2 Japan
        • 6.3.3.3.2.1 Japan Cell and Gene Therapy Biomanufacturing Market (by Product Type)
        • 6.3.3.3.2.2 Japan Cell and Gene Therapy Biomanufacturing Market (by End User)
      • 6.3.3.3.3 India
        • 6.3.3.3.3.1 India Cell and Gene Therapy Biomanufacturing Market (by Product Type)
        • 6.3.3.3.3.2 India Cell and Gene Therapy Biomanufacturing Market (by End User)
      • 6.3.3.3.4 South Korea
        • 6.3.3.3.4.1 South Korea Cell and Gene Therapy Biomanufacturing Market (by Product Type)
        • 6.3.3.3.4.2 South Korea Cell and Gene Therapy Biomanufacturing Market (by End User)
      • 6.3.3.3.5 Australia/New Zealand
        • 6.3.3.3.5.1 Australia/New Zealand Cell and Gene Therapy Biomanufacturing Market (by Product Type)
        • 6.3.3.3.5.2 Australia/New Zealand Cell and Gene Therapy Biomanufacturing Market (by End User)
      • 6.3.3.3.6 Rest-of-Asia-Pacific
        • 6.3.3.3.6.1 Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Product Type)
        • 6.3.3.3.6.2 Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by End User)
• 6.4 Latin America
  • 6.4.1 Key Findings and Opportunity Assessment
  • 6.4.2 Market Dynamics
    • 6.4.2.1 Impact Analysis
  • 6.4.3 Sizing and Forecast Analysis
    • 6.4.3.1 Latin America Cell and Gene Therapy Biomanufacturing Market (by Product Type)
    • 6.4.3.2 Latin America Cell and Gene Therapy Biomanufacturing Market (by End User)
    • 6.4.3.3 Latin America Cell and Gene Therapy Biomanufacturing Market (by Country)
      • 6.4.3.3.1 Argentina
        • 6.4.3.3.1.1 Argentina Cell and Gene Therapy Biomanufacturing Market (by Product Type)
        • 6.4.3.3.1.2 Argentina Cell and Gene Therapy Biomanufacturing Market (by End User)
      • 6.4.3.3.2 Brazil
        • 6.4.3.3.2.1 Brazil Cell and Gene Therapy Biomanufacturing Market (by Product Type)
        • 6.4.3.3.2.2 Brazil Cell and Gene Therapy Biomanufacturing Market (by End User)
      • 6.4.3.3.3 Mexico
        • 6.4.3.3.3.1 Mexico Cell and Gene Therapy Biomanufacturing Market (by Product Type)
        • 6.4.3.3.3.2 Mexico Cell and Gene Therapy Biomanufacturing Market (by End User)
      • 6.4.3.3.4 Rest-of-Latin America
        • 6.4.3.3.4.1 Rest-of-Latin America Cell and Gene Therapy Biomanufacturing Market (by Product Type)
        • 6.4.3.3.4.2 Rest-of-Latin America Cell and Gene Therapy Biomanufacturing Market (by End User)
• 6.5 Middle East and Africa
  • 6.5.1 Key Findings and Opportunity Assessment
  • 6.5.2 Market Dynamics
    • 6.5.2.1 Impact Analysis
  • 6.5.3 Sizing and Forecast Analysis
    • 6.5.3.1 Middle East and Africa Cell and Gene Therapy Biomanufacturing Market (by Product Type)
    • 6.5.3.2 Middle East and Africa Cell and Gene Therapy Biomanufacturing Market (by End User)
    • 6.5.3.3 Middle East and Africa Cell and Gene Therapy Biomanufacturing Market (by Country)
      • 6.5.3.3.1 Kingdom of Saudi Arabia
        • 6.5.3.3.1.1 Kingdom of Saudi Arabia Cell and Gene Therapy Biomanufacturing Market (by Product Type)
        • 6.5.3.3.1.2 Kingdom of Saudi Arabia Cell and Gene Therapy Biomanufacturing Market (by End User)
      • 6.5.3.3.2 U.A.E.
        • 6.5.3.3.2.1 U.A.E. Cell and Gene Therapy Biomanufacturing Market (by Product Type)
        • 6.5.3.3.2.2 U.A.E. Cell and Gene Therapy Biomanufacturing Market (by End User)
      • 6.5.3.3.3 Israel
        • 6.5.3.3.3.1 Israel Cell and Gene Therapy Biomanufacturing Market (by Product Type)
        • 6.5.3.3.3.2 Israel Cell and Gene Therapy Biomanufacturing Market (by End User)
      • 6.5.3.3.4 Rest-of-Middle East and Africa
        • 6.5.3.3.4.1 Rest-of-Middle East and Africa Cell and Gene Therapy Biomanufacturing Market (by Product Type)
        • 6.5.3.3.4.2 Rest-of-Middle East and Africa Cell and Gene Therapy Biomanufacturing Market (by End User)

7 Markets - Competitive Benchmarking and Company Profiles

• 7.1 Competitive Benchmarking
  • 7.1.1 Competitive Landscape
    • 7.1.1.1 Segmental Growth Share Matrix
      • 7.1.1.1.1 Growth Share Analysis (by Product Type)
      • 7.1.1.1.2 Growth Share Analysis (by Application)
    • 7.1.1.2 Competitive Index (Unmet Needs and Innovations)
    • 7.1.1.3 Company Position Analysis
    • 7.1.1.4 Key Strategies and Developments
      • 7.1.1.4.1 Funding Activities
      • 7.1.1.4.2 New Offerings
      • 7.1.1.4.3 Mergers and Acquisitions
      • 7.1.1.4.4 Partnerships, Alliances, and Business Expansions
      • 7.1.1.4.5 Key Development Analysis
• 7.2 Company Share Analysis
• 7.3 Company Profiles
  • 7.3.1 Becton, Dickinson and Company
    • 7.3.1.1 Company Overview
    • 7.3.1.2 Role of Becton, Dickinson and Company in the Global Cell and Gene Therapy Biomanufacturing Market
    • 7.3.1.3 Major Product: Key Specifications
    • 7.3.1.4 Customers and Competitions/Opportunities
      • 7.3.1.4.1 Key Customers
      • 7.3.1.4.2 Key Competitors
    • 7.3.1.5 Analyst Perspective
  • 7.3.2 Bio-Rad Laboratories, Inc.
    • 7.3.2.1 Company Overview
    • 7.3.2.2 Role of Bio-Rad Laboratories, Inc. in the Global Cell and Gene Therapy Biomanufacturing Market
    • 7.3.2.3 Major Product: Key Specifications
    • 7.3.2.4 Customers and Competitions/Opportunities
      • 7.3.2.4.1 Key Customers
      • 7.3.2.4.2 Key Competitors
    • 7.3.2.5 Analyst Perspective
  • 7.3.3 Bio-Techne Corporation
    • 7.3.3.1 Company Overview
    • 7.3.3.2 Role of Bio-Techne Corporation in the Global Cell and Gene Therapy Biomanufacturing Market
    • 7.3.3.3 Major Product: Key Specifications
    • 7.3.3.4 Customers and Competitions/Opportunities
      • 7.3.3.4.1 Key Competitors
    • 7.3.3.5 Analyst Perspective
  • 7.3.4 Danaher Corporation
    • 7.3.4.1 Company Overview
    • 7.3.4.2 Role of Danaher Corporation in the Global Cell and Gene Therapy Biomanufacturing Market
    • 7.3.4.3 Major Product: Key Specifications
    • 7.3.4.4 Customers and Competitions/Opportunities
      • 7.3.4.4.1 Key Competitors
    • 7.3.4.5 Analyst Perspective
  • 7.3.5 Endress+Hauser Group Services AG (Analytik Jena GmbH)
    • 7.3.5.1 Company Overview
    • 7.3.5.2 Role of Endress+Hauser Group Services AG (Analytik Jena GmbH) in the Global Cell and Gene Therapy Biomanufacturing Market
    • 7.3.5.3 Major Product: Key Specifications
    • 7.3.5.4 Customers and Competitions/Opportunities
      • 7.3.5.4.1 Key Customers
      • 7.3.5.4.2 Key Competitors
    • 7.3.5.5 Analyst Perspective
  • 7.3.6 General Electric Company (GE Healthcare)
    • 7.3.6.1 Company Overview
    • 7.3.6.2 Role of General Electric (GE HealthCare) in the Global Cell and Gene Therapy Biomanufacturing Market
    • 7.3.6.3 Major Product: Key Specifications
    • 7.3.6.4 Customers and Competitions/Opportunities
      • 7.3.6.4.1 Key Competitors
    • 7.3.6.5 Analyst Perspective
  • 7.3.7 Getinge AB
    • 7.3.7.1 Company Overview
    • 7.3.7.2 Role of Getinge AB in the Global Cell and Gene Therapy Biomanufacturing Market
    • 7.3.7.3 Major Product: Key Specifications
    • 7.3.7.4 Customers and Competitions/Opportunities
      • 7.3.7.4.1 Key Competitors
    • 7.3.7.5 Analyst Perspective
  • 7.3.8 Infors AG
    • 7.3.8.1 Company Overview
    • 7.3.8.2 Role of Infors AG in the Global Cell and Gene Therapy Biomanufacturing Market
    • 7.3.8.3 Major Product: Key Specifications
    • 7.3.8.4 Customers and Competitions/Opportunities
      • 7.3.8.4.1 Key Competitors
    • 7.3.8.5 Analyst Perspective
  • 7.3.9 Lonza Group Ltd
    • 7.3.9.1 Company Overview
    • 7.3.9.2 Role of Lonza Group Ltd in the Global Cell and Gene Therapy Biomanufacturing Market
    • 7.3.9.3 Major Product: Key Specifications
    • 7.3.9.4 Customers and Competitions/Opportunities
      • 7.3.9.4.1 Key Competitors
    • 7.3.9.5 Analyst Perspective
  • 7.3.10 Merck KGaA
    • 7.3.10.1 Company Overview
    • 7.3.10.2 Role of Merck KGaA in the Global Cell and Gene Therapy Biomanufacturing Market
    • 7.3.10.3 Major Product: Key Specifications
    • 7.3.10.4 Customers and Competitions/Opportunities
      • 7.3.10.4.1 Key Competitors
    • 7.3.10.5 Analyst Perspective
  • 7.3.11 Miltenyi Biotec B.V. & Co. KG
    • 7.3.11.1 Company Overview
    • 7.3.11.2 Role of Miltenyi Biotec B.V. & Co. KG in the Global Cell and Gene Therapy Biomanufacturing Market
    • 7.3.11.3 Major Product: Key Specifications
    • 7.3.11.4 Customers and Competitions/Opportunities
      • 7.3.11.4.1 Key Customers
      • 7.3.11.4.2 Key Competitors
    • 7.3.11.5 Analyst Perspective
  • 7.3.12 PIERRE GUERIN
    • 7.3.12.1 Company Overview
    • 7.3.12.2 Role of PIERRE GUERIN in the Global Cell and Gene Therapy Biomanufacturing Market
    • 7.3.12.3 Major Product: Key Specifications
    • 7.3.12.4 Customers and Competitions/Opportunities
      • 7.3.12.4.1 Key Competitors
    • 7.3.12.5 Analyst Perspective
  • 7.3.13 Sartorius AG (Sartorius Stedim Biotech S.A.)
    • 7.3.13.1 Company Overview
    • 7.3.13.2 Role of Sartorius AG (Sartorius Stedim Biotech S.A.) in the Global Cell and Gene Therapy Biomanufacturing Market
    • 7.3.13.3 Major Product: Key Specifications
    • 7.3.13.4 Customers and Competitions/Opportunities
      • 7.3.13.4.1 Key Customers
      • 7.3.13.4.2 Key Competitors
    • 7.3.13.5 Analyst Perspective
  • 7.3.14 Thermo Fisher Scientific Inc.
    • 7.3.14.1 Company Overview
    • 7.3.14.2 Role of Thermo Fisher Scientific Inc. in the Global Cell and Gene Therapy Biomanufacturing Market
    • 7.3.14.3 Major Product: Key Specifications
    • 7.3.14.4 Customers and Competitions/Opportunities
      • 7.3.14.4.1 Key Competitors
    • 7.3.14.5 Analyst Perspective
  • 7.3.15 WuXi AppTec
    • 7.3.15.1 Company Overview
    • 7.3.15.2 Role of WuXi AppTec in the Global Cell and Gene Therapy Biomanufacturing Market
    • 7.3.15.3 Major Product: Key Specifications
    • 7.3.15.4 Customers and Competitions/Opportunities
      • 7.3.15.4.1 Key Competitors
    • 7.3.15.5 Analyst Perspective
• 7.4 Emerging Companies
  • 7.4.1 elevatebio
  • 7.4.2 Adva Biotechnology
  • 7.4.3 Vineti

List of Figures

• Figure 1: Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
• Figure 2: Cell and Gene Therapy Biomanufacturing Market: Drivers, Restraints, and Opportunities
• Figure 3: Global Cell and Gene Therapy Biomanufacturing Market, Impact Analysis
• Figure 4: Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion, 2021-2031
• Figure 5: Global Cell and Gene Therapy Biomanufacturing Market (by Region), $Billion, 2021 and 2031
• Figure 6: Global Cell and Gene Therapy Biomanufacturing Market, Share of Key Developments and Strategies (by Category), January 2020-January 2023
• Figure 7: Global Cell and Gene Therapy Biomanufacturing Market Segmentation
• Figure 8: Global Cell and Gene Therapy Biomanufacturing Market: Research Methodology
• Figure 9: Primary Research Methodology
• Figure 10: Bottom-Up Approach (Segment-Wise Analysis)
• Figure 11: Top-Down Approach (Segment-Wise Analysis)
• Figure 12: Global Cell and Gene Therapy Biomanufacturing Market, Potential Forecast Scenarios
• Figure 13: Global Cell and Gene Therapy Biomanufacturing Market Size and Growth Potential (Realistic Scenario), Billion, 2021-2031
• Figure 14: Global Cell and Gene Therapy Biomanufacturing Market Size and Growth Potential (Optimistic Scenario), $Billion, 2021-2031
• Figure 15: Global Cell and Gene Therapy Biomanufacturing Market Size and Growth Potential (Pessimistic Scenario), $Billion, 2021-2031
• Figure 16: Market Overview and Ecosystem
• Figure 17: Insights on Strategies Adopted by Major Players, January 2020-January 2023
• Figure 18: Global Cell and Gene Therapy Biomanufacturing Market, Key Trends, Market Shift, 2022-2031
• Figure 19: TcBuster vs. Viral Gene Engineering Technology, Comparative Analysis
• Figure 20: Global Cell and Gene Therapy Biomanufacturing Market, Patent Analysis (by Year), January 2020-December 2022
• Figure 21: Global Cell and Gene Therapy Biomanufacturing Market, Patent Analysis (by Country), January 2020-December 2022
• Figure 22: Anticipated Regulatory Milestones in 2023
• Figure 23: Anticipated Regulatory Approval, U.S. and EU, 2023
• Figure 24: Global Cell and Gene Therapy Biomanufacturing Market, Technology Adoption Matrix
• Figure 25: Global Cell and Gene Therapy Biomanufacturing Market, Key Success Factors
• Figure 26: FDA-Approved Cell and Gene Therapies, 2011-2022
• Figure 27: Global Incidence of Hematologic Malignancies (Leukemia, Multiple Myeloma and Immunoproliferative Diseases, and Non-Hodgkin's Lymphoma), 2020 vs. 2040
• Figure 28: Number of Cell and Gene Therapy Developers (by Region)
• Figure 29: Global Investment in Cell and Gene Therapy Market, 2017-2022
• Figure 30: Volume and Value of Start-Up Financing, 2020-2021
• Figure 31: Ongoing Clinical Trials, Cell and Gene Therapies
• Figure 32: Impact of COVID-19 on CGT Developmental Activities
• Figure 33: Progress in Cell and Gene Therapy (CGT) Regulation during COVID-19
• Figure 34: Ways to Increase Supply Chain and Manufacturing
• Figure 35: Impact on Biopharmaceutical Industries
• Figure 36: Global Cell and Gene Therapy Biomanufacturing Market (by Product Type)
• Figure 37: Global Cell and Gene Therapy Biomanufacturing Market Incremental Opportunity (by Product Type), $Billion, 2021-2031
• Figure 38: Global Cell and Gene Therapy Biomanufacturing Market (Consumables), $Billion, 2021-2031
• Figure 39: Global Cell and Gene Therapy Biomanufacturing Market (Culture Supplements), $Billion, 2021-2031
• Figure 40: Global Cell and Gene Therapy Biomanufacturing Market (Media), $Billion, 2021-2031
• Figure 41: Global Cell and Gene Therapy Biomanufacturing Market (Serum), $Billion, 2021-2031
• Figure 42: Types of Macronutrients in Cell Culture Supplements
• Figure 43: Global Cell and Gene Therapy Biomanufacturing Market (Macronutrients), $Billion, 2021-2031
• Figure 44: Advantages of Using Single-Use Liquids
• Figure 45: Global Cell and Gene Therapy Biomanufacturing Market (Single-Use Liquids), $Billion, 2021-2031
• Figure 46: Global Cell and Gene Therapy Biomanufacturing Market (Cell Culture Reagents), $Billion, 2021-2031
• Figure 47: Global Cell and Gene Therapy Biomanufacturing Market (Cell Quantification Kits), $Billion, 2021-2031
• Figure 48: Global Cell and Gene Therapy Biomanufacturing Market (Equipment), $Billion, 2021-2031
• Figure 49: Global Cell and Gene Therapy Biomanufacturing Market (Bioreactors/Fermenters), $Billion, 2021-2031
• Figure 50: Global Cell and Gene Therapy Biomanufacturing Market (Continuous Bioreactors), $Billion, 2021-2031
• Figure 51: Global Cell and Gene Therapy Biomanufacturing Market (Single-Use Bioreactors), $Billion, 2021-2031
• Figure 52: Global Cell and Gene Therapy Biomanufacturing Market (Mixing Systems), $Billion, 2021-2031
• Figure 53: Global Cell and Gene Therapy Biomanufacturing Market (Cell Counters), $Billion, 2021-2031
• Figure 54: Global Cell and Gene Therapy Biomanufacturing Market (Cell Sorters), $Billion, 2021-2031
• Figure 55: Global Cell and Gene Therapy Biomanufacturing Market (Centrifuges), $Billion, 2021-2031
• Figure 56: Global Cell and Gene Therapy Biomanufacturing Market (Incubators), $Billion, 2021-2031
• Figure 57: Classes of Biosafety Cabinets
• Figure 58: Global Cell and Gene Therapy Biomanufacturing Market (Biosafety Cabinets), $Billion, 2021-2031
• Figure 59: Global Cell and Gene Therapy Biomanufacturing Market (Freezers), $Billion, 2021-2031
• Figure 60: Global Cell and Gene Therapy Biomanufacturing Market (PCR Systems), $Billion, 2021-2031
• Figure 61: Global Cell and Gene Therapy Biomanufacturing Market (Transfection Systems), $Billion, 2021-2031
• Figure 62: Global Cell and Gene Therapy Biomanufacturing Market (Storage Tanks), $Billion, 2021-2031
• Figure 63: Global Cell and Gene Therapy Biomanufacturing Market (Others), $Billion, 2021-2031
• Figure 64: Global Cell and Gene Therapy Biomanufacturing Market (Software Solutions), $Billion, 2021-2031
• Figure 65: Global Cell and Gene Therapy Biomanufacturing (by Application)
• Figure 66: Global Cell and Gene Therapy Biomanufacturing Market Incremental Opportunity (by Application), $Billion, 2021-2031
• Figure 67: Steps in Upstream Processing
• Figure 68: Global Cell and Gene Therapy Biomanufacturing Market (Upstream Processing), $Billion, 2021-2031
• Figure 69: Global Cell and Gene Therapy Biomanufacturing Market (Formulation and Hydration), $Billion, 2021-2031
• Figure 70: Steps in Cell Culture Processing
• Figure 71: Global Cell and Gene Therapy Biomanufacturing Market (Cell Culture Processing), $Billion, 2021-2031
• Figure 72: Global Cell and Gene Therapy Biomanufacturing Market (Harvesting), $Billion, 2021-2031
• Figure 73: Steps in Downstream Processing
• Figure 74: Global Cell and Gene Therapy Biomanufacturing Market (Downstream Processing), $Billion, 2021-2031
• Figure 75: Global Cell and Gene Therapy Biomanufacturing Market (Separation and Filtration), $Billion, 2021-2031
• Figure 76: Steps Involved in Fill and Finish Operations
• Figure 77: Global Cell and Gene Therapy Biomanufacturing Market (Fill and Finish Operations), $Billion, 2021-2031
• Figure 78: Global Cell and Gene Therapy Biomanufacturing Market (by Usage)
• Figure 79: Global Cell and Gene Therapy Biomanufacturing Market Incremental Opportunity (by Usage), $Billion, 2021-2031
• Figure 80: Important Steps in the Commercial Stage of Manufacturing
• Figure 81: Global Cell and Gene Therapy Biomanufacturing Market (Commercial Stage Manufacturing), $Billion, 2021-2031
• Figure 82: Global Cell and Gene Therapy Biomanufacturing Market (Research Stage Manufacturing), $Billion, 2021-2031
• Figure 83: Global Cell and Gene Therapy Biomanufacturing Market (by End User)
• Figure 84: Global Cell and Gene Therapy Biomanufacturing Market Incremental Opportunity (by End User), $Billion, 2021-2031
• Figure 85: Global Cell and Gene Therapy Biomanufacturing Market (Life Sciences Companies), $Billion, 2021-2031
• Figure 86: Global Cell and Gene Therapy Biomanufacturing Market (Equipment), $Billion, 2021-2031
• Figure 87: Global Cell and Gene Therapy Biomanufacturing Market (Consumables), $Billion, 2021-2031
• Figure 88: Global Cell and Gene Therapy Biomanufacturing Market (Software Solutions), $Billion, 2021-2031
• Figure 89: Global Cell and Gene Therapy Biomanufacturing Market (Contract Research Organizations (CROs)), $Billion, 2021-2031
• Figure 90: Global Cell and Gene Therapy Biomanufacturing Market (Equipment), $Billion, 2021-2031
• Figure 91: Global Cell and Gene Therapy Biomanufacturing Market (Consumables), $Billion, 2021-2031
• Figure 92: Global Cell and Gene Therapy Biomanufacturing Market (Software Solutions), $Billion, 2021-2031
• Figure 93: Global Cell and Gene Therapy Biomanufacturing Market (Contract Manufacturing Organizations (CMOs)), $Billion, 2021-2031
• Figure 94: Global Cell and Gene Therapy Biomanufacturing Market (Equipment), $Billion, 2021-2031
• Figure 95: Global Cell and Gene Therapy Biomanufacturing Market (Consumables), $Billion, 2021-2031
• Figure 96: Global Cell and Gene Therapy Biomanufacturing Market (Software Solutions), $Billion, 2021-2031
• Figure 97: Global Cell and Gene Therapy Biomanufacturing Market (Cell Banks), $Billion, 2021-2031
• Figure 98: Global Cell and Gene Therapy Biomanufacturing Market (Equipment), $Billion, 2021-2031
• Figure 99: Global Cell and Gene Therapy Biomanufacturing Market (Consumables), $Billion, 2021-2031
• Figure 100: Global Cell and Gene Therapy Biomanufacturing Market (Software Solutions), $Billion, 2021-2031
• Figure 101: Global Cell and Gene Therapy Biomanufacturing Market Share (by Region)
• Figure 102: North America Cell and Gene Therapy Biomanufacturing Market Incremental Revenue Opportunity (by Country), $Billion, 2021-2031
• Figure 103: Ongoing Clinical Trials, North America (by Country)
• Figure 104: Leukemia, Incidence, 2020 vs. 2040
• Figure 105: Multiple Myeloma and Immunoproliferative Diseases, Incidence, 2020 vs. 2040
• Figure 106: North America Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
• Figure 107: North America Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion, 2021-2031
• Figure 108: North America Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion, 2021-2031
• Figure 109: Rate of Hematologic Malignancies (by Age and Cancer Type), U.S.
• Figure 110: U.S. Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
• Figure 111: U.S. Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
• Figure 112: U.S. Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
• Figure 113: Incidence of Multiple Myeloma and Immunoproliferative Diseases and Non-Hodgkin's Lymphoma, Canada, 2020 vs. 2040
• Figure 114: Canada Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
• Figure 115: Canada Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
• Figure 116: Canada Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
• Figure 117: Europe Cell and Gene Therapy Biomanufacturing Market Incremental Revenue Opportunity (by Country), $Billion, 2021-2031
• Figure 118: Ongoing Clinical Trials, Europe (by Country)
• Figure 119: Leukemia, Incidence, 2020 vs. 2040
• Figure 120: Multiple Myeloma, Incidence, 2020 vs. 2040
• Figure 121: Non-Hodgkin's Lymphoma, Incidence, 2020 vs. 2040
• Figure 122: Europe Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
• Figure 123: Europe Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion, 2021-2031
• Figure 124: Europe Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion, 2021-2031
• Figure 125: Incidence of Leukemia, Multiple Myeloma, and Non-Hodgkin's Lymphoma, Germany, 2020 vs. 2040
• Figure 126: Germany Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
• Figure 127: Germany Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
• Figure 128: Germany Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
• Figure 129: Italy Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
• Figure 130: Italy Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
• Figure 131: Italy Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
• Figure 132: Incidence of Leukemia, Multiple Myeloma, and Non-Hodgkin's Lymphoma, U.K., 2020 vs. 2040
• Figure 133: U.K. Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
• Figure 134: U.K. Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
• Figure 135: U.K. Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
• Figure 136: Incidence of Leukemia, Multiple Myeloma, and Non-Hodgkin's Lymphoma, Spain, 2020 vs. 2040
• Figure 137: Spain Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
• Figure 138: Spain Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
• Figure 139: Spain Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
• Figure 140: Incidence of Leukemia, Multiple Myeloma, and Non-Hodgkin's Lymphoma, France, 2020 vs. 2040
• Figure 141: France Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
• Figure 142: France Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
• Figure 143: France Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
• Figure 144: Rest-of-Europe Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
• Figure 145: Rest-of-Europe Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
• Figure 146: Rest-of-Europe Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
• Figure 147: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market Incremental Revenue Opportunity (by Country), $Billion, 2021-2031
• Figure 148: Ongoing Clinical Trials, Asia-Pacific (by Country)
• Figure 149: Incidence of Hematologic Malignancies, Asia, 2020 vs. 2040
• Figure 150: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
• Figure 151: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion, 2021-2031
• Figure 152: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion, 2021-2031
• Figure 153: China Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
• Figure 154: China Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
• Figure 155: China Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
• Figure 156: Japan Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
• Figure 157: Japan Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
• Figure 158: Japan Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
• Figure 159: Incidence of Leukemia, Multiple Myeloma and Immunoproliferative Diseases, and Non-Hodgkin's Lymphoma, India, 2020 vs. 2040
• Figure 160: India Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
• Figure 161: India Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
• Figure 162: India Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
• Figure 163: Incidence of Leukemia, Multiple Myeloma and Immunoproliferative Diseases, and Non-Hodgkin's Lymphoma, South Korea, 2020 vs. 2040
• Figure 164: South Korea Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
• Figure 165: South Korea Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
• Figure 166: South Korea Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
• Figure 167: Australia/New Zealand Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
• Figure 168: New Zealand Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
• Figure 169: Australia/New Zealand Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
• Figure 170: Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
• Figure 171: Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
• Figure 172: Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
• Figure 173: Latin America Cell and Gene Therapy Biomanufacturing Market Incremental Revenue Opportunity (by Country), $Billion, 2021-2031
• Figure 174: Ongoing Clinical Trials, Latin America (by Country)
• Figure 175: Leukemia, Multiple Myeloma and Immunoproliferative Diseases, and Non-Hodgkin's Lymphoma, Incidence, Latin America and Caribbean, 2020 vs. 2040
• Figure 176: Latin America Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
• Figure 177: Latin America Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion, 2021-2031
• Figure 178: Latin America Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion, 2021-2031
• Figure 179: Incidence of Leukemia, Multiple Myeloma and Immunoproliferative Diseases, and Non-Hodgkin's Lymphoma, Argentina, 2020 vs. 2040
• Figure 180: Argentina Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
• Figure 181: Argentina Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
• Figure 182: Argentina Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
• Figure 183: Incidence of Myeloma and Immunoproliferative Diseases and Non-Hodgkin's Lymphoma, Brazil, 2020 vs. 2040
• Figure 184: Brazil Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
• Figure 185: Brazil Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
• Figure 186: Brazil Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
• Figure 187: Incidence of Leukemia and Non-Hodgkin's Lymphoma, Mexico, 2020 vs. 2040
• Figure 188: Mexico Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
• Figure 189: Mexico Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
• Figure 190: Mexico Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
• Figure 191: Rest-of-Latin America Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
• Figure 192: Rest-of-Latin America Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
• Figure 193: Rest-of-Latin America Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
• Figure 194: Middle East and Africa Cell and Gene Therapy Biomanufacturing Market Incremental Revenue Opportunity (by Country), $Billion, 2021-2031
• Figure 195: Incidence of Hematologic Cancers (Leukemia, Multiple Myeloma and Immunoproliferative Diseases, and Non-Hodgkin's Lymphoma), Africa, 2020 vs. 2040
• Figure 196: Ongoing Clinical Trials, Middle East and Africa (by Country)
• Figure 197: Middle East and Africa Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
• Figure 198: Middle East and Africa Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion, 2021-2031
• Figure 199: Middle East and Africa Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion, 2021-2031
• Figure 200: Kingdom of Saudi Arabia Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
• Figure 201: Kingdom of Saudi Arabia Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
• Figure 202: Kingdom of Saudi Arabia Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
• Figure 203: Incidence of Multiple Myeloma and Immunoproliferative Diseases and Non-Hodgkin's Lymphoma, U.A.E., 2020 vs. 2040
• Figure 204: U.A.E. Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
• Figure 205: U.A.E. Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
• Figure 206: U.A.E. Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
• Figure 207: Incidence of Leukemia and Non-Hodgkin's Lymphoma, Israel, 2020 vs. 2040
• Figure 208: Israel Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
• Figure 209: Israel Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
• Figure 210: Israel Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
• Figure 211: Rest-of-Middle East and Africa Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
• Figure 212: Rest-of-Middle East and Africa Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
• Figure 213: Rest-of-Middle East and Africa Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
• Figure 214: Growth Share Analysis for Global Cell and Gene Therapy Biomanufacturing Market (by Product Type), 2021-2031
• Figure 215: Growth Share Analysis for Global Cell and Gene Therapy Biomanufacturing Market (by Application), 2021-2031
• Figure 216: Competitive Index, Unmet Needs, Solutions, and Impacts
• Figure 217: Company Position Analysis
• Figure 218: Global Cell and Gene Therapy Biomanufacturing Market, Total Number of Key Developments, January 2020-January 2023
• Figure 219: Funding Activities, January 2020-January 2023
• Figure 220: New Offerings, January 2020-September 2023
• Figure 221: Mergers and Acquisitions, January 2020-January 2023
• Figure 222: Partnerships, Alliances, and Business Expansion Activities, January 2020-January 2023
• Figure 223: Global Cell and Gene Therapy Biomanufacturing Market, Company Share Analysis, % Share, 2021
• Figure 224: Becton, Dickinson and Company: Product Portfolio
• Figure 225: Bio-Rad Laboratories, Inc.: Product Portfolio
• Figure 226: Bio-Techne Corporation: Product Portfolio
• Figure 227: Danaher Corporation: Product Portfolio
• Figure 228: Endress+Hauser Group Services AG (Analytik Jena GmbH): Product Portfolio
• Figure 229: General Electric Company (GE Healthcare): Product Portfolio
• Figure 230: Getinge AB: Product Portfolio
• Figure 231: Infors AG: Product Portfolio
• Figure 232: Lonza Group Ltd: Product Portfolio
• Figure 233: Merck KGaA: Product Portfolio
• Figure 234: Miltenyi Biotec B.V. & Co. KG: Product Portfolio
• Figure 235: PIERRE GUERIN: Product Portfolio
• Figure 236: Sartorius AG (Sartorius Stedim Biotech S.A.): Product Portfolio
• Figure 237: Thermo Fisher Scientific Inc.: Product Portfolio
• Figure 238: WuXi AppTec: Product Portfolio

List of Tables

• Table 1: Key Questions Answered in the Report
• Table 2: Parameters for Realistic, Optimistic, and Pessimistic Growth Scenarios
• Table 3: Single-Use and Stainless-Steel Facilities, Comparative Analysis
• Table 4: Global Regulatory Scenario: Cell and Gene Therapy Biomanufacturing Market
• Table 5: Global Cell and Gene Therapy Biomanufacturing Market (by Product Type), Product Benchmarking
• Table 6: Comparative Analysis of Various Bioreactors Offered by Key Players
• Table 7: Global Cell and Gene Therapy Biomanufacturing Market, Awaited Technologies
• Table 8: Business Models, Key Features
• Table 9: Impact Analysis, Business Drivers
• Table 10: Impact Analysis, Business Restraints
• Table 11: Cell Culture Flask and Automated System, Comparative Analysis
• Table 12: North America Cell and Gene Therapy Biomanufacturing Market Dynamics, Impact Analysis
• Table 13: Europe Cell and Gene Therapy Biomanufacturing Market Dynamics, Impact Analysis
• Table 14: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market Dynamics, Impact Analysis
• Table 15: Approved Cell and Gene Therapies, Japan
• Table 16: Ongoing Industry Sponsored Cell and Gene Therapy Clinical Trials
• Table 17: Latin America Cell and Gene Therapy Biomanufacturing Market Dynamics, Impact Analysis
• Table 18: Middle East and Africa Cell and Gene Therapy Biomanufacturing Market Dynamics, Impact Analysis
• Table 19: Global Cell and Gene Therapy Biomanufacturing Market, Key Development Analysis, January 2020-January 2023